Adding apalutamide (Erleada) to androgen deprivation therapy (ADT) in patients with biochemically recurrent prostate cancer reduced the risk of developing metastases and castration-resistant disease, according to findings from the phase 3 PRESTO…
Apalutamide/ADT Improves Long-Term Outcomes in Biochemically Recurrent Prostate Cancer | Targeted Oncology
